fda compounding semaglutide enforcement november 2025 news Have patients been harmed by unsafe drug compounding? – Partnership for Safe Medicines fda compounding semaglutide enforcement news
Description
Successfully represented a hotel owner in a defective work claim against a general contractor where the hotel was suffering water damage, obtaining a settlement payment from the contractors insurance carrier exceeding $700,000
Starting with lower doses and gradually increasing can help minimize these early symptoms
Controls appetite
Summary: Retatrutide is an investigational triple incretin receptor agonist not licensed in the UK and not supported by clinical evidence for muscle growth
Some people may experience increased heart rate, dry mouth, insomnia, or restlessness while taking tesofensine
Be careful with claims that use medical language while still labelling the product for research use
